Skip to main content
. Author manuscript; available in PMC: 2012 Sep 4.
Published in final edited form as: Oncol Rep. 2011 Jan 14;25(3):855–862. doi: 10.3892/or.2011.1147

Figure 1.

Figure 1

Bevacizumab inhibits growth of endometrial cancer in mouse xenograft model. Athymic mice injected with Hec50co endometrial cancer cells were treated with vehicle control (saline, n=8) or bevacizumab (n=16) for 5 weeks. Tumor growth in mice in control (closed circles ●) and bevacizumab (open circles ○) treated groups was estimated weekly for 5 weeks. Differences in tumor size (mm2) were assessed by ANOVA and post-hoc Bonferroni’s test. *Indicates statistically significant differences between groups (p≤0.05) and #indicates that tumor sizes differ significantly between control and experimental groups at week 5 of treatment (p≤0.05).